Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

TLR2 joins the interferon gang.

Bauernfeind F, Hornung V.

Nat Immunol. 2009 Nov;10(11):1139-41. doi: 10.1038/ni1109-1139.

PMID:
19841644
2.

Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands.

Barbalat R, Lau L, Locksley RM, Barton GM.

Nat Immunol. 2009 Nov;10(11):1200-7. doi: 10.1038/ni.1792. Epub 2009 Oct 4. Erratum in: Nat Immunol. 2010 Jun;11(6):543.

3.

MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2.

Davies ML, Sei JJ, Siciliano NA, Xu RH, Roscoe F, Sigal LJ, Eisenlohr LC, Norbury CC.

J Virol. 2014 Mar;88(6):3557-67. doi: 10.1128/JVI.02776-13. Epub 2014 Jan 8.

4.

TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN amplification loop.

Wenink MH, Santegoets KC, Broen JC, van Bon L, Abdollahi-Roodsaz S, Popa C, Huijbens R, Remijn T, Lubberts E, van Riel PL, van den Berg WB, Radstake TR.

J Immunol. 2009 Dec 1;183(11):6960-70. doi: 10.4049/jimmunol.0900713. Epub 2009 Nov 13.

5.

CD11b⁺, Ly6G⁺ cells produce type I interferon and exhibit tissue protective properties following peripheral virus infection.

Fischer MA, Davies ML, Reider IE, Heipertz EL, Epler MR, Sei JJ, Ingersoll MA, Rooijen NV, Randolph GJ, Norbury CC.

PLoS Pathog. 2011 Nov;7(11):e1002374. doi: 10.1371/journal.ppat.1002374. Epub 2011 Nov 10.

6.

Antiviral effect of bacterially produced human interferon (Hu-IFN alpha 2) against experimental vaccinia infection in calves.

Werenne J, Vanden Broecke C, Schwers A, Goossens A, Bugyaki L, Maenhoudt M, Pastoret PP.

J Interferon Res. 1985 Winter;5(1):129-36.

PMID:
3989335
7.

New developments in the induction and antiviral effectors of type I interferon.

Liu SY, Sanchez DJ, Cheng G.

Curr Opin Immunol. 2011 Feb;23(1):57-64. doi: 10.1016/j.coi.2010.11.003. Epub 2010 Nov 29. Review.

8.

In vivo immune stimulation by interferon during viral infection.

Schellekens H, Weimar W, De Reus A, Bolhuis RL, Cantell K.

Antiviral Res. 1981 Sep;1(3):179-83.

PMID:
6175277
9.

Interleukin-15 mediates potent antiviral responses via an interferon-dependent mechanism.

Foong YY, Jans DA, Rolph MS, Gahan ME, Mahalingam S.

Virology. 2009 Oct 25;393(2):228-37. doi: 10.1016/j.virol.2009.07.030. Epub 2009 Sep 3.

10.

The effects of recombinant and natural human interferons in vaccinia virus infected rhesus monkeys.

van der Meide PH, Harteveld N, Stebbing N, Schellekens H.

Antiviral Res. 1985;Suppl 1:199-207. No abstract available.

PMID:
3936413
11.

Commensal bacteria lipoteichoic acid increases skin mast cell antimicrobial activity against vaccinia viruses.

Wang Z, MacLeod DT, Di Nardo A.

J Immunol. 2012 Aug 15;189(4):1551-8. doi: 10.4049/jimmunol.1200471. Epub 2012 Jul 6.

12.

MITAgating viral infection.

Zeng W, Chen ZJ.

Immunity. 2008 Oct 17;29(4):513-5. doi: 10.1016/j.immuni.2008.09.010.

13.

The PPE18 of Mycobacterium tuberculosis interacts with TLR2 and activates IL-10 induction in macrophage.

Nair S, Ramaswamy PA, Ghosh S, Joshi DC, Pathak N, Siddiqui I, Sharma P, Hasnain SE, Mande SC, Mukhopadhyay S.

J Immunol. 2009 Nov 15;183(10):6269-81. doi: 10.4049/jimmunol.0901367. Epub 2009 Oct 30.

14.

Temporal relationship of interferon production and resistance to experimentally induced virus infection.

Ash RJ, Bubel HC.

J Infect Dis. 1966 Feb;116(1):1-7. No abstract available.

PMID:
5908851
15.

[The relationship between individual interferon production and the skin reaction of rabbits to vaccinia virus].

Bektemorov TA, Parushina AE.

Vopr Virusol. 1971 Jul-Aug;16(4):466-8. Russian. No abstract available.

PMID:
5137547
16.

Type I interferon response to cytomegalovirus infection: the kick-start.

Fodil-Cornu N, Vidal SM.

Cell Host Microbe. 2008 Feb 14;3(2):59-61. doi: 10.1016/j.chom.2008.01.005. Review.

17.

Initiation of primary anti-vaccinia virus immunity in vivo.

Fischer MA, Norbury CC.

Immunol Res. 2007;37(2):113-33. Review.

PMID:
17695247
18.

Zoonotic vaccinia virus: clinical and immunological characteristics in a naturally infected patient.

Trindade GS, Guedes MI, Drumond BP, Mota BE, Abrahão JS, Lobato ZI, Gomes JA, Corrêa-Oliveira R, Nogueira ML, Kroon EG, da Fonseca FG.

Clin Infect Dis. 2009 Feb 1;48(3):e37-40. doi: 10.1086/595856.

19.

Role of antibody in recovery from severe vaccinia virus infection.

Worthington M.

Clin Infect Dis. 2003 Sep 15;37(6):864-5; author reply 865-6. No abstract available.

20.

Inhibiting effect of increasing body-weight on the lethal response of DBA-I mice to vaccinia virus infection.

Duran-Reynals ML.

Nature. 1966 Apr 16;210(5033):332-4. No abstract available.

PMID:
5954584
Items per page

Supplemental Content

Write to the Help Desk